NCT04200690 (NCAS-1) is a NA clinical trial of Interdisciplinary management in Psoriasis, sponsored by University of Aarhus.

Who is sponsoring NCT04200690?

NCT04200690 is sponsored by University of Aarhus.

What drugs are being tested in NCT04200690?

Interventions in NCT04200690: Interdisciplinary management, Usual-care management.

What condition does NCT04200690 study?

NCT04200690 studies Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa, Crohn Disease, Ulcerative Colitis.

Is NCT04200690 still recruiting?

NCT04200690 is currently status unknown. Last updated 2 June 2023.

Last reviewed 2023-06-02 · How we verify

NCT04200690: NCAS-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of Interdisciplinary Care Compared to Usual Care in Patients With Immune-Mediated Inflammatory Diseases

Status unknown NA Last updated 2 June 2023

What this trial tests

NA trial testing Interdisciplinary management in Psoriasis in 300 participants. Status unknown.

Timeline

14 January 2020

Primary endpoint
31 January 2023

31 January 2024

Quick facts

Lead sponsor	University of Aarhus
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	300
Start date	14 January 2020
Primary completion	31 January 2023
Estimated completion	31 January 2024
Sites	1 location across Denmark

Drugs / interventions tested

Interdisciplinary management
Usual-care management

Conditions studied

Psoriasis — all drugs for Psoriasis →
Psoriatic Arthritis — all drugs for Psoriatic Arthritis →
Axial Spondyloarthritis — all drugs for Axial Spondyloarthritis →
Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →

Sponsor

University of Aarhus

Who can join

18 and older, any sex, with Psoriasis or Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall aim of this study is to determine the effectiveness of an interdisciplinary combined clinic intervention compared to usual care in a population of patients with two or more Immune-mediated inflammatory diseases (IMIDs).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Hidradenitis Suppurativa: Where We Are and Where We Are Going.
Scala E, Cacciapuoti S, Garzorz-Stark N, Megna M, et al · · 2021 · cited 85× · PMID 34440863 · DOI 10.3390/cells10082094
Effectiveness of interdisciplinary combined dermatology-gastroenterology-rheumatology clinical care compared to usual care in patients with immune-mediated inflammatory diseases: a parallel group, non-blinded, pragmatic randomised trial.
Hjuler KF, Dige A, Agnholt J, Laurberg TB, et al · · 2021 · cited 17× · PMID 33910945 · DOI 10.1136/bmjopen-2020-041871
Cross-speciality collaborative care in complex immune-mediated inflammatory diseases: treating the person living with the condition.
Taylor PC, Savage L, Bundy C, Langmead L, et al · · 2025 · PMID 41462202 · DOI 10.1186/s12916-025-04483-3

Verify or expand the search:

Other trials of Interdisciplinary management

Trials testing the same drug.

NCT06069011 — Direct Access Physiotherapy in the Pediatric Emergency Department · NA · completed

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other University of Aarhus trials

Trials by the same sponsor.

NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04200690 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
Last refreshed: 2 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04200690.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing